Gufic BiosciencesBOM:509079 +1.45%76 Interest Coverage is 4.19 as of Mar. 2026, which is 8% below its 10-year median of 4.56. GuruFocus rates BOM:509079 with a GF Score™ of 76/100 and a GF Value™ of ₹407.90 (Fairly Valued). The stock has 6 warning signs investors should review. Among 686 Drug Manufacturers companies, Gufic Biosciences ranks worse than 77.55% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Gufic Biosciences's
Operating Income
for the
three
months ended in Mar. 2026 was ₹396 Mil. Gufic Biosciences's Interest Expense for the
three
months ended in Mar. 2026 was ₹-94 Mil.
Gufic Biosciences's interest coverage for the quarter that ended in Mar. 2026 was 4.19.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Gufic Biosciences's Interest Coverage or its related term are showing as below:
BOM:509079'
s Interest Coverage Range Over the Past 10 Years
Min: 3.1 Med: 4.56 Max: 32.22
Current: 3.29
BOM:509079's Interest Coverage is ranked worse than 77.55% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs BOM:509079: 3.29
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Gufic Biosciences Interest Coverage Related Terms
Gufic Biosciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:509079 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences (BOM:509079) has a Interest Coverage of 4.19 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Gufic Biosciences and its competitors. This is near median its historical median of 4.56. Over the past decade, Gufic Biosciences' Interest Coverage has ranged from 3.10 to 32.22. According to the industry distribution chart, Gufic Biosciences ranks #532 out of 686 companies in the Drug Manufacturers industry, placing it in the top 77.6%.
Is Gufic Biosciences' Interest Coverage too high?
Gufic Biosciences' current Interest Coverage of 4.19 is near median its 10-year median of 4.56. Over the past 10 years, this metric has ranged from a low of 3.10 to a high of 32.22. The Drug Manufacturers industry median Interest Coverage is 12.73. Gufic Biosciences' value of 4.19 is 67.1% below this industry median. Based on the distribution chart, Gufic Biosciences ranks #532 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gufic Biosciences has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #532 out of 686 companies for Interest Coverage. This places Gufic Biosciences in the lower half of its industry. The industry median Interest Coverage is 12.73. Gufic Biosciences' value of 4.19 is 67.1% below this benchmark. Historically, Gufic Biosciences' own Interest Coverage has ranged from 3.10 to 32.22 over the past decade. While the company's 10-year median is 4.56 vs. the industry median of 12.73, Gufic Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gufic Biosciences's current Interest Coverage of 4.19 is 67.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current Interest Coverage is 4.19, which is near median its own 10-year median of 4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹407.90, compared to a current price of ₹391.00 — trading 4.1% below its estimated fair value. The current Interest Coverage is 4.19, which is near median its 10-year median of 4.56 and 67.1% below the Drug Manufacturers industry median of 12.73. Gufic Biosciences' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Interest Coverage is 4.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹391.00 is trading 4.1% below its estimated GF Value™ of ₹407.90.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
Interest Coverage: 4.19 (near median its 10-year median of 4.56)
GF Value™: ₹407.90 vs. price of ₹391.00 (4.1% below fair value)
Industry Position: 67.1% below the Drug Manufacturers median (#532 of 686)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
76GF Score
Get the complete analysis for BOM:509079
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
